培美曲赛与多西他赛单药二线治疗局部晚期非小细胞肺癌的疗效对比

目的:对比培美曲赛与多西他赛单药二线治疗局部晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效。方法:将98例晚期NSCLC患者根据入院顺序按随机数字表法分为培美曲赛组与多西他赛组,每组各49例。培美曲赛组给予培美曲赛化疗,多西他赛组给予多西他赛化疗。对比两组近期疗效、生存质量及不良反应发生情况。结果:治疗后,两组总有效率、疾病控制率、躯体、角色认知功能及整体生活质量方面比较差异统计学意义(P>0.05)。培美曲赛组1年生存率为25.57%(14/49),多西他赛组1年生存率为18.36%(9/49),两组比较差异无统计学意义(P>0.05)。不良反应方面,培美曲赛组白细胞减少、恶心呕吐及脱发的发生率明显低于多西他赛组(P<0.05或P<0.01),放射性食管炎、放射性肺炎、血小板减少及皮疹的发生率两组差异无统计学意义(P>0.05)。结论:培美曲赛单药治疗局部晚期NSCLC的临床疗效与多西他赛相当,但毒副作用较小,安全性更高。

Comparison of clinical efficacy of second-line treatment of single pemetrexed and docetaxel for patients with local advanced non-small cell lung cancer

Objective:To compare the clinical efficacy of second-line treatment of single Pemetrexed and Docetaxel for patients with local advanced non-small cell lung cancer (NSCLC).Methods:A total of 98 patients with NCSLC were randomly divided into pemetrexed group treated with pemetrexed and docetaxel group with docetaxel,49 cases for each group.Short-term clinical efficacy,quality of life (QOL) and rates of adverse reactions were compared between two groups.Results:There were no significant difference between two groups in total response rate,disease control rate,body and role cognitive function and total QOL after treatment (P>0.05).The one-year survival rate was 25.57%(14/49) in pemetrexed group and 18.36%(9/49) in docetaxel group,there was no significant difference (P>0.05).As to the adverse reactions,pemetrexed group was markedly lower than docetaxel group in the rates of leucopenia,nausea and vomiting, and alopecia(P<0.05 or P<0.01),but there were no significant difference between two groups in the rates of radioactive esophagitis,radioactive pneumonia,thrombocytopenia and rash (P>0.05).Conclusion:Single pemetrexed is similar to docetaxel in the clinical efficacy,but is lower in adverse and toxic reactions and higher in safety in the treatment of local advanced NSCLC.